Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648607 | 0.86 | GNAI3 (0.46) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL21791674 | 0.84 | KDM4E (0.38) | GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL18922338 | 0.83 | GNAI3 (0.56) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL13369708 | 0.79 | GNAI3 (0.46) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL24975560 | 0.79 | OPRL1 (0.35) | — | |
| SCHEMBL28514340 | 0.79 | GNAO1 (0.55) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL19826326 | 0.78 | GNAI3 (0.46) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL18922344 | 0.73 | GNAI3 (0.53) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL1197783 | 0.73 | GNAI3 (0.68) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL1198152 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | GNAI3 1955/4885GNAO1 3070/4885GNAI1 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.